MYCOF - Mydecine Innovations Group announces 1-for-50 reverse stock split

Biotechnology company Mydecine Innovations Group (OTCPK:MYCOF) on Wednesday announced a 1-for-50 reverse stock split, wherein every 50 common shares will be consolidated into 1 common share. The reverse stock split is expected to result in Mydecine's outstanding common shares being reduced from 268.5M to about 5.4M. The expected effective date of the split will be April 20, and the post-consolidation common shares will start trading on the NEO exchange as of April 21.

For further details see:

Mydecine Innovations Group announces 1-for-50 reverse stock split